The bioavailability of cytarabine in dogs with meningoencephalitis of unknown etiology through iontophoresis and rectal delivery.
Open Vet J
; 11(1): 36-38, 2021.
Article
em En
| MEDLINE
| ID: mdl-33898281
ABSTRACT
Background:
Cytarabine (CA) is used to treat dogs with meningoencephalitis of unknown etiology (MUE) by subcutaneous or intravenous administration.Aim:
The objective was to investigate transdermal iontophoresis and rectal administration as alternative routes of CA delivery.Methods:
Two client-owned dogs with MUE were studied. The ActivaPatch® IONTOGO™ 12.0 iontophoresis drug delivery system delivered 200 mg/m2 CA transdermally. Blood samples were collected by sparse sampling technique after initiation of the device. At another visit, 100 mg/m2 CA was administered rectally. Blood samples were collected by sparse sampling technique after administration. Plasma CA concentrations were measured by high-pressure liquid chromatography.Results:
The concentration of plasma CA after transdermal and rectal administration was below the limits of quantification (0.1 µg/ml) in all samples suggesting inadequate bioavailability with transdermal and rectal administration.Conclusion:
Transdermal and rectal CA administration are not reasonable alternative routes of delivery.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Administração Retal
/
Iontoforese
/
Citarabina
/
Imunossupressores
/
Injeções
Tipo de estudo:
Etiology_studies
Idioma:
En
Revista:
Open Vet J
Ano de publicação:
2021
Tipo de documento:
Article